Literature DB >> 29931103

Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis.

Hajime Uno1, Lu Tian2, Lee-Jen Wei3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29931103      PMCID： PMC7020855          DOI： 10.1001/jamaoncol.2018.1087

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

2.  Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Authors:  Kyongsun Pak; Hajime Uno; Dae Hyun Kim; Lu Tian; Robert C Kane; Masahiro Takeuchi; Haoda Fu; Brian Claggett; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

3.  Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Wendy Cooper; Matthew Links; Val Gebski; Roy S Herbst; Richard J Gralla; Tony Mok; James Chih-Hsin Yang
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777
  3 in total
  1 in total

1.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.